Outcome heterogeneity and bias in acute experimental Spinal Cord Injury – a meta-analysis by Watzlawick, Ralf et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome heterogeneity and bias in acute experimental Spinal
Cord Injury – a meta-analysis
Citation for published version:
Watzlawick, R, Antonic, A, Sena, E, Kopp, MA, Rind, J, Dirnagl, U, MacLeod, M, Howells, DW & Schwab,
JM 2019, 'Outcome heterogeneity and bias in acute experimental Spinal Cord Injury – a meta-analysis',
Neurology. https://doi.org/10.1212/WNL.0000000000007718
Digital Object Identifier (DOI):
10.1212/WNL.0000000000007718
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Neurology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 12. Jun. 2020
ARTICLE
Outcome heterogeneity and bias in acute
experimental spinal cord injury
A meta-analysis
Ralf Watzlawick, MD, Ana Antonic, PhD, Emily S. Sena, PhD, Marcel A. Kopp, MD, Julian Rind, MS,
Ulrich Dirnagl, MD, Malcolm Macleod, MD, David W. Howells, PhD,* and Jan M. Schwab, MD, PhD*
Neurology® 2019;93:e1-e12. doi:10.1212/WNL.0000000000007718
Correspondence
Dr. Schwab
jan.schwab@osumc.edu
Abstract
Objective
To determine whether and to what degree bias and underestimated variability undermine the
predictive value of preclinical research for clinical translation.
Methods
We investigated experimental spinal cord injury (SCI) studies for outcome heterogeneity and
the impact of bias. Data from 549 preclinical SCI studies including 9,535 animals were analyzed
with meta-regression to assess the effect of various study characteristics and the quality of
neurologic recovery.
Results
Overall, the included interventions reported a neurobehavioral outcome improvement of 26.3%
(95% confidence interval 24.3–28.4). Response to treatment was dependent on experimental
modeling paradigms (neurobehavioral score, site of injury, and animal species). Applying
multiple outcome measures was consistently associated with smaller effect sizes compared with
studies applying only 1 outcome measure. More than half of the studies (51.2%) did not report
blinded assessment, constituting a likely source of evaluation bias, with an overstated effect size
of 7.2%. Assessment of publication bias, which extrapolates to identify likely missing data,
suggested that between 2% and 41% of experiments remain unpublished. Inclusion of these
theoretical missing studies suggested an overestimation of efficacy, reducing the effect sizes by
between 0.9% and 14.3%.
Conclusions
We provide empirical evidence of prevalent bias in the design and reporting of experimental
SCI studies, resulting in overestimation of the effectiveness. Bias compromises the internal
validity and jeopardizes the successful translation of SCI therapies from the bench to bedside.
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From Charite´–Universita¨tsmedizin Berlin (R.W., M.A.K., J.R., U.D., J.M.S.), corporate member of the Freie Universita¨t Berlin, Humboldt-Universita¨t zu Berlin, and Berlin Institute of
Health; Department of Neurology and Experimental Neurology (R.W., M.A.K., J.R., J.M.S.), Charite´ Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory
(Neuroparaplegiology), Charite´–Universita¨tsmedizin Berlin; Department of Neurosurgery (R.W.), Freiburg University Medical Center, Germany; Department of Neuroscience (A.A.),
Central Clinical School, Monash University, Melbourne; Stroke Division (E.S.S., M.M., D.W.H.), Melbourne, Victoria, Australia; Departments of Neurology and of Clinical Neurosciences
(E.S.S., M.M.), University of Edinburgh, UK; Center for Stroke Research Berlin (U.D.) and Excellence Cluster Neurocure (U.D.), Charité–Universita ̈tsmedizin, Berlin, Germany; German
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Traumatic spinal cord injury (SCI) affects hundreds of
thousands of patients worldwide every year, and it is esti-
mated that up to 5 million patients are currently affected by
the chronic consequences of SCI.1,2 Despite successful
improvements in the prevention of traumatic spinal cord
injuries, it has been predicted that the growing population
will result in a stable or even an increased total number of
patients with SCI.3 However, limited financial resources,
heterogeneous lesions, and small numbers of clinical trials
impair clinical translation. Finding new treatments for these
individuals relies on animal models of SCI. These are be-
lieved to have good face validity and to be sufficiently like
SCI in humans to make them highly relevant for trans-
lation.4 This holds true as long as known translational
limitations are taken into account. These include differences
in locomotion (quadrupedal locomotion in rodent mod-
els5), neural innervation relevant for locomotion or fine
motor control,6,7 different injury paradigms (sustained cord
compression,8 concomitant injury of nerve roots in human
SCI5), inflammatory responses,9 and other aspects of the
physiology and pathophysiology of experimental SCI in
rodents. In addition to cross-species differences, methodo-
logic shortcomings are also believed to contribute to
translational failure (translational roadblock) of animal
model–derived findings.10–12 To determine the extent to
which avoidable methodologic limitations apply to experi-
mental SCI research, we aimed to characterize the impact of
study design, study quality, and bias. To do so, we have
performed a meta-analysis of published data from SCI ani-
mal studies. These techniques allowed us to interrogate data
from larger numbers of animals, reducing the effect of in-
dividual underpowered studies. Insufficient statistical power
has been identified as a major independent shortcoming
limiting the translational and predictive value of animal
models.13,14
The medical need for developing new therapies emphasizes
the necessity for preclinical animal studies to generate clin-
ically valuable (translational) data. This requires the as-
sessment of confounding variables, which might impair the
signal-to-noise ratio and reduce the likelihood of detecting
an effect.
Risk of experimental and publication bias limits the value of the
published literature on drug testing because both lead to
overestimation of effect size. Given that systematic reviews and
meta-analyses have identified limited internal validity (e.g., due
to bias) associated with inflated effect sizes in preclinical is-
chemic brain injury studies,12 we investigate whether and to
what degree preventable bias also influences experimental SCI
studies. The pragmatic Collaborative Approach to Meta-
Analysis and Review of Animal Data From Experimental
Studies (CAMARADES) approach has value in determining
the likelihood that a particular dataset is subject to these
problems.
In this meta-analysis and meta-regression, we determine the
impact of study characteristics, methodologic and reporting
bias, and common meta-epidemiologic characteristics on
neurobehavioral recovery after experimental SCI in a large
cohort of 9,535 animals.
Methods
Literature search
This study includes data stored in the CAMARADES data-
base. The CAMARADES database contains preclinical animal
data for various diseases (e.g., stroke, SCI, myocardial in-
farction, neuropathic pain) hosted at the University of Edin-
burgh since 2004. Access to the CAMARADES database is
internationally available on request. For this study, all avail-
able SCI animal data were selected from the database in
September 2015, including 6 independently assessed litera-
ture analyses of different SCI interventions: decompression,
hypothermia, pharmaceutical inhibitors of the Rho/ROCK
pathway, cellular treatment (stem cells, olfactory ensheathing
glia [OEG]), and physical exercise after the injury. All of the
corresponding study protocols and a protocol of this meta-
analysis were finalized in advance of any data collection and
are accessible online (dcn.ed.ac.uk/camarades/research.
html#protocols). Five of those 6 studies have already been
published as systematic reviews and meta-analyses.15–20 Eli-
gibility criteria differ moderately among the included studies,
but each reported locomotor recovery in experimental SCI
models. We excluded studies that did not report the number
of animals in each group, the mean effect size, and its variance.
The initial literature searches in 3 online databases (PubMed,
EMBASE, and ISI Web of Science) were performed until
October 2014 for studies published before then and were
screened by 2 independent investigators. The searches within
the databases were not restricted to specific years.
Data extraction
Study characteristics from each publication were extracted
into the CAMARADES database as outlined in previous
reviews.15–20 In brief, when a single publication reported >1
experiment, they were treated as independent experiments.
Glossary
BBB = Basso, Beattie, Bresnahan; BMS = Basso Mouse Scale for Locomotion; CAMARADES = Collaborative Approach to
Meta-Analysis and Review of Animal Data From Experimental Studies; CI = confidence interval;OEG = olfactory ensheathing
glia; SCI = spinal cord injury.
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For experiments reporting the improvement of a functional
outcome measured by a neurobehavioral score, only the final
time points were extracted. Studies were excluded if they did
not report the number of animals in each group, the mean
effect size and its SD, or SEM. Where various outcome
measurements were reported for the same group of animals,
we pooled those containing a value for multiple scales. The
quality of each study was assessed with a modified 9-point
checklist21 (1) reporting of a sample size calculation, (2)
control of the animals’ temperature, (3) use of anesthetics
other than ketamine (because of its marked intrinsic neuro-
protective activity), (4) randomized treatment allocation, (5)
treatment allocation concealment, (6) blinded assessment of
outcome, (7) publication in a peer-reviewed journal; (8)
statement of compliance with regulatory requirements, and
(9) statement of potential conflicts of interest.
Analysis
The normalized effect size (normalized mean difference) was
calculated for each experimental comparison as the pro-
portional improvement in the treated compared to the control
group, along with a standard error of this estimate. When
a single control group served multiple treatment groups, the
size of the control group was adjusted to account for this. This
corrected number was used for any further calculation and in
the weighting of effect sizes.22
We stratified the analysis according to (1) the applied treat-
ment, (2) the neurobehavioral score used (Basso, Beattie,
Bresnahan [BBB] score23; Basso Mouse Scale for Locomo-
tion [BMS]24; Tarlov scale25; others), (3) the model and level
of the injury, (4) study characteristics (time to treatment, time
of outcome assessment, animal sex and strain), (5) anesthetic
regimen (anesthetic used and method of ventilation), and (6)
methodologic quality of the studies according to the 9-point
checklist. Cohorts within a stratification accounting for >1%
of the total animal number were considered an individual
group. Smaller cohorts accounting for <1% were grouped
together and referred to as others.
We applied random-effect meta-analysis regression to calculate
an overall treatment effect, combining efficacy across studies to
assess significant differences between the groups for each
stratification criteria. Meta-regression with the metareg func-
tion of STATA/SE13 (StataCorp, College Station, TX) was
used,26 and the significance level was set at p = 0.05. The meta-
regressionwas performed in a univariatemanner becausemajor
concerns about the reliability of multivariate analysis have been
raised with the need for further statistical investigation.27 Ad-
justed R2 values were calculated to assess how much residual
heterogeneity was explained by each independent variable
within a stratified dataset.22 The adjusted R2 is defined as the
ratio of explained variance of the respective stratification to
total variance (of all experiments together). Higher R2 values
are indicative of a higher explanatory value of this stratification.
Restricted maximum likelihood was used to estimate the ad-
ditive (between-study) component of variance tau2 within the
meta-regression.26 The dependent variable was, in all cases, the
normalized effect size.
Funnel plots28 and trim and fill analyses29,30 were performedwith
the metatrim function of STATA/SE13. The Duval and Twee-
die29 nonparametric trim and fill method estimates the number of
missing studies (publication bias) that might have been per-
formed but are not available for ameta-analysis using simple rank-
based data augmentation techniques adjusted for missing studies.
Normalized mean difference (effect size) was plotted against
precision (1/SEM). The metabias function detects the presence
of publication bias by Egger regressionmeasured by the intercept
from standard normal deviates against precision.31 Figures were
drawn with SigmaPlot (Systat Software Inc, San Jose, CA).
Data availability
Data not provided in the article will be shared at the request of
other investigators for purposes of replicating procedures and
results.
Results
Selection of datasets and study details
The CAMARADES database contained details on 549
experiments from 303 included publications from 1967 to
2014 reporting functional improvement assessed by neuro-
behavioral scores (table 1).
We included data from 9,535 animals. Overall, the number of
control animals used was 20% smaller than the number that
received treatment (control animals n = 3,765, 39.5%; treated
animals n = 5,770, 60.5%). Six different animal species were
used to investigate therapeutic interventions for SCI: 8,108
rats (85%), 1,199 mice (12.6%), 107 dogs (1.1%), 57 mon-
keys (0.6%), 44 rabbits (0.5%), and 20 sheep (0.2%).
Study characteristics and their impact on
neurobehavioral outcome
Random-effect meta-regression revealed an overall effect size
of 26.3% (95% confidence interval [CI] 24.3–28.3, I2 =
98.6%) when all included neurobehavioral scores were com-
bined. To explore sources of heterogeneity, we applied meta-
regression and identified several study design characteristics
accounting for significant within- and between-study hetero-
geneity (figures 1 and 2). Study characteristics are represented
in terms of prevalence (width of the bar indicating the number
of studies) and variability (CI).
Animal model
Experimental SCI in rats constituted themost prevalent injury
paradigm and outnumbered mouse SCI, even though the
latter offers the advantage of genetic manipulation (figure
1A). Variability as indicated by 95% CIs was larger in mice
compared to rats. Effect sizes for larger animal SCI models,
including dogs, monkeys, rabbits, and sheep, applied mostly
customized scoring systems and were generally larger and
linked to greater variability (R2 = 8.0%, p < 0.0001).
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Neurobehavioral scale
Multiple neurobehavioral outcome scales were used to assess
functional recovery after SCI (figure 1B). The BBB or
BMS23,24 score for locomotion was most commonly applied,
accounting for 66.7% (6,302 of 9,462 animals). The 21-point
BBB score evaluates hind-limbmovement and fore/hind-limb
coordination in an open field test in rats, whereas the BMS
score is adapted to recovery patterns in mice.23,24 BBB and
BMS scores reported similar improvement of locomotion
within the overall analysis (figure 1B, red square). BBB and
BMS scores were also associated with the smallest measure-
ment variability (CI). The effect size was lowest in cases when
multiple assessments (>1 outcome measurement reported in
a study) were used (R2 = 14.7%, p < 0.0001). Animals assessed
with the outdated Tarlov scale showed the greatest im-
provement. Despite considerable differences in SCI lesion
neuropathology between rats and mice (cavity formation,
inflammatory response),32,33 the relative amounts of recovery
and responder rates after experimental SCI on mice (BMS)
and rats (BBB) were comparable.
Blinded assessment of outcome
Regarding the hypothesis that lack of reporting on study
quality criteria is associated with variations in effect sizes, 2
main quality characteristics revealed statistically significant
results: blinding of experiments and whether compliance with
animal welfare was reported (figure 1, C and D). Fewer than
half (48.8%) of the interventional studies reported that they
were conducted in a blinded manner. Lack of blinding results
in evaluation bias that reduces the internal reliability of the
experiment and accounts for significantly inflated effect sizes
by 7.2% (R2 = 2.6%, p = 0.001) (figure 1C).
Compliance with animal welfare
Reported compliance with animal welfare protocols was
lacking in 29.5% (n = 2,815) of the studies. Studies lacking
reported compliance were associated with 5.6% larger effect
sizes and larger variability (figure 1D). The reporting of
statement of compliance (R2 = 2.0%, p = 0.015) and blinding
during outcome assessment were significantly associated with
different effect sizes, both representing items of the 9-point
quality checklist.21,22
Impact of the design of experimental SCI
studies on neurologic recovery in
rodent models
To address the possibility that differences in effect sizes can be
attributed to the distinct scoring systems applied to rodent
and large animal models, we performed a subanalysis for
a BBB/BMS score only population (figure 2). Similar BBB
(rat) and BMS (mouse) effect sizes (figure 1B) ensure suffi-
cient comparability as the basis to study the relevance of
distinct experimental designs for neurologic recovery. For the
BBB/BMS only population, meta-regression calculated an
effect size of 24.0% (95% CI 21.9–26.2, I2 = 98.9%; table 2).
Type of treatment
We compared quantitative data about SCI interventions rel-
evant for clinical SCI ranging from acute care to chronic SCI.
These include decompression, hypothermia, pharmaceutical
(Rho/ROCK pathway) and cellular treatments (stem cells,
OEGs), and rehabilitative interventions (voluntary and forced
exercise). Acute care interventions are associated throughout
with higher effect sizes compared with rehabilitative inter-
ventions such as exercise (figure 2A). Improvement in motor
Table 1 Characteristics of different interventions included in the overall analysis
Decompression Exercise Hypothermia OEG
Rho/ROCK
inhibitors Stem cells Overall
Publications, n (%) 21 (6.9) 25 (8.3) 16 (5.3) 51 (16.8) 14 (4.6) 176 (58.1) 303
Experiments, n (%) 79 (14.4) 36 (6.6) 25 (4.6) 62 (11.3) 30 (5.5) 317 (57.7) 549
Animals, n (%) 873 (9.2) 575 (6.0) 448 (4.7) 1,164 (12.2) 655 (6.7) 5,820 (61.0) 9,535
BBB scale, n (%) 246 (3.4) 498 (6.8) 218 (3.0) 1,027 (14.0) 524 (7.2) 4,811 (65.7) 7,324
BMS score, n (%) 0 55 (12.6) 0 0 131 (30.0) 250 (57.3) 436
Multiple, n (%) 282 (15.1) 398 (21.4) 101 (5.4) 0 0 1,083 (58.1) 1864
Inclined plane, n (%) 295 (90.2) 0 32 (9.8) 0 0 0 327
Tarlov scale, n (%) 27 (8.6) 0 88 (27.9) 0 0 200 (63.5) 315
Others, n (%) 151 (23.1) 14 (2.1) 99 (15.1) 137 (20.9) 0 253 (38.7) 654
Overall effect size,
(% improvement in
outcome score)
34.2 (27.4–41.1) 13.1
(4.9–21.4)
29.1
(17.1–41.1)
23.6
(17.3–30.0)
23.2 (14.1–32.4) 27.1
(24.5–29.7)
26.3
(24.3–28.4)
Abbreviations: BBB = Basso, Beattie, and Bresnahan; BMS = Basso Mouse Scale; OEG = olfactory ensheathing glia.
Cumulative number of publications, number of experiments, included animals, applied outcomemeasures, and effect size calculated bymeta-regression for
all outcome measurements are given. Largest effect sizes relate to spinal decompression surgery and hypothermia. Note that multiple outcome meas-
urements contain experiments assessing various outcome measures for a specific animal group (e.g., BBB score and Tarlov scale).
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outcome after SCI was most pronounced for decompression
surgery (27.1%), followed by stem cells (26.2%), Rho/ROCK
inhibition (21.3%), and hypothermia (16.3%). Exercise
demonstrated the lowest effect sizes (14.4%). Stem cell
transplantation studies accounted for 65.3% of the total
number of animals (R2 = 3.0%, p = 0.0022) included in this
subanalysis.
Level of injury
The most prevalent lesion level location was Th8, followed by
Th9, and Th10 (figure 2B). Level of injury affects the effect
size, with closer proximity of the lesion to deafferentated af-
ferent target (in the lumbosacral motor pools) resulting in
larger effect sizes, mimicking an exponential curve function
(R2 = 4.5%, p = 0.0047). Interpretation of the high cervical
SCI data is limited further by small sample size, large variance,
and the use of less severe lesion paradigms. Thus, experi-
mental SCI is dominated by low thoracic SCI paradigms.
Sex
Female rodents outnumbered males (58.2% females, 27.4%
males; figure 2C). Studies including both sexes were charac-
terized by a larger variability resulting in an extended CI (R2 =
3.5%, p = 0.0018).
Type of injury
SCI was induced with 5 different types of injury (figure 2D).
Contusion and transection were the most severe injuries and
produced the smallest interventional effect. Static compres-
sion was associated with slightly better effect sizes, followed
by hemisection. Photochemical injuries (focal topical appli-
cation of high-energy light or chemicals) were rarely applied
and induced only minor injury, associated with the largest
improvement responses in motor score (R2 = 3.8%, p =
0.005). Contusion SCI was by far the most prevalent injury
paradigm (n = 3,983 animals).
Figure 1Neurologic recovery after SCI (effect size):meta-regression stratifying for animal species, neurobehavioral scores,
and study quality
Stratifications of study characteristics within the overall dataset, comprising all reported neurobehavioral outcome scores and animal species. (A) Rat
constitutes themost prevalent spinal cord injury SCImodel, followed bymice, whereas large animal spinal cord injury (SCI) models, including dogs, monkeys,
rabbits, and sheep, are rare and characterized by customized scoring systems with larger effect sizes and extended variability. (B) Various neurobehavioral
outcome scaleswere used to assess functional recovery after SCI in the overall dataset. The Basso, Beattie, andBresnahan (BBB) score andBassoMouse Scale
(BMS) score for locomotion were identified as the most commonly used scores and reported similar improvement of locomotion. The homogeneous BBB/
BMS only cohort (red square) was assessed in a separate subanalysis. (C) Fewer than half (48.8%) of the interventional studies reported that they were
conducted in a blindedmanner, with a difference of 7.2% in the calculated effect sizes. (D) Reported compliance with animal welfare protocols was lacking in
29.5% of the studies, which were associated with 5.6% larger effect sizes and larger variability. Gray bars represent the 95% confidence interval (CI) of the
global estimate (neurologic recovery). Vertical error bars show the 95% CI of individual means. Width of each bar indicates percentage of reported animals
number per specified item. Asterisks indicate stratification items forwhich the barwidthwas broadened later for better visibility. All stratifications account for
a significant proportion of between-study heterogeneity (p < 0.02).
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Figure 2 Effect of study characteristics on locomotor recovery after rodent SCI (BBB/BMS only cohort)
Differential aspects of spinal cord injury (SCI) modeling on neurologic recovery were assessed by including only studies that applied Basso, Beattie, and
Bresnahan (BBB) or Basso Mouse Scale (BMS) scores. This homogeneous cohort (red square, B) comprises 6,048 of 9,535 animals (63.4%). (A) Six different
interventions were included in the meta-regression. (B) Lesion-level matter. A more rostral lesion level (high thoracic) along the neuraxis resulted in smaller
outcome gain compared to more distal thoracic lesions. High cervical (C2-C4) lesion levels were considered a separate cohort in this regard in that only
unilateral hemisections can be performed at those levels because complete transections or severe contusions are technically challenging or will otherwise
cause immediate death of the animal. (C) Female rodents constitute the main cohort tested in experimental SCI. (D) Severe contusion and complete
transection injuries resulted in the most impaired neurologic function and lowest effect size, followed by static clip compression. Hemisection and photo-
chemical injuries (focal topical application of high-energy light and/or chemicals) induced only minor injury, associated with the largest improvement. (E)
Geographic location of the experimental laboratory influenced the amount of reported neurologic recovery. Individual countries were identified if they
contributed >200 animals to the dataset. (F) Effect size of the investigated intervention decreased with extended assessment period after SCI. Effect size
depended on the duration of the assessment and started to intermittently drop below the average with observational time frames >8 weeks, whereas the
variability remained similar. Gray bars represent the 95% confidence interval (CI) of the global estimate (neurologic recovery). Vertical error bars show the
95% CI of individual means. Width of each bar indicates the percentage of reported animal numbers per specified item. Asterisks indicate stratification items
for which the bar width was broadened later for better visibility. All stratifications account for a significant proportion of between-study heterogeneity (p <
0.001). OEG = olfactory ensheathing glia.
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Location of the laboratory
The regional location of the experimental laboratory affected
the reported effect size (figure 2E). Most of the animal
experiments were performed in China, the United States, and
Japan (R2 = 8.3%, p < 0.0001). Studies from China and
Australia were associated with large effect sizes, while studies
from Brazil, Sweden, the United States, and Canada were
associated with the smallest effect sizes. The required number
of total animals for each listed country was 200, excluding
those otherwise assigned to others.
Time point of assessment
Studies including long-term outcomes (>2-month assessment
time frame) were underrepresented. The effect size of the
investigated intervention decreased with extended assessment
period after SCI, starting to intermittently drop below the
average with observational time frames >8 weeks. Declining
effect sizes after 8 weeks point to the risk that interventions
provided only transient benefits, diminishing with time and
therefore unlikely to translate into long-term results. This is in
line with interventions that are able to trigger faster recovery
but fail to reach higher functional plateaus at longer follow-up.
The pattern of diminished effect size was not dependent on
early vs late intervention. This rules out the possibility that
decreasing effect sizes after 8 weeks resulted from more
studies testing delayed applications. Variability was the high-
est in cases when the observational time was not indicated (R2
= 4.6%, p = 0.0017; figure 2F).
Detection of publication bias (missing data)
When considering all studies of the homogeneous BBB/BMS
only cohort (table 2) comprising data from 6,302 animals
stratified for the type of intervention, we observed an over-
estimation of efficacy due to missing data. Funnel plotting and
trim and fill analysis indicated that data were missing in 4
types of SCI interventions. The reported effect size in each
study was adjusted for absolute overestimation of efficacy for
each study ranging between 0.9% (OEG) and 14.3% (de-
compression) (figure 3 and table 2). Assessment of the
missing data/publication bias with the trim and fill method
suggested that the number of missing experiments varies
among the tested interventions, ranging from 0% (stem cells,
hypothermia) to 1.9% (OEG), 20% (exercise), 30% (Rho/
ROCK inhibition), and 40.9% (decompression). Data asym-
metry indicative of missing data was confirmed by Egger re-
gression, suggesting significant bias in the BBB/BMS only
datasets.
Geographic differences
To explore the differences attributable to the region-specific
effect sizes (table 3), we focused on a comparison of the 3
countries with high study numbers and comparably small CIs
(Unites States, Japan, and China). We excluded data from
other countries with considerably lower study numbers (in-
dicated by smaller bar width, figure 2E) because the analysis
would have been underpowered. Between-country differences
may be related to varying percentages of interventions asso-
ciated with larger effect sizes (percentage of stem cell studies:
China 31.3%, Japan 25.5%, and United States 17.3%). How-
ever, when we focused on stem cell interventions only,
a similar geographic pattern was observed, with the highest
effect size (31.3%) observed in studies from Chinese labora-
tories compared to studies from Japan (25.5%) or the United
States (17.3%). When we compared the effect sizes of re-
covery after complete transection as a defined injury type, the
response to treatment was highest in studies from China
(28.2%), followed by Japan (9.3%) and the United States
(8.5%). An association of poor study quality (characterized by
the quality score) with larger therapeutic effect sizes has been
reported earlier in other CNS lesion paradigms and is
Table 2 Analysis of the BBB/BMS only cohort after correction for missing data (delta inflation)
Intervention
Reported
effect size
(random
metatrim),
% (95% CI)
Adjusted effect size
(random),
% (95% CI)
Filled experiments
(was), n
Absolute overestimation of
efficacy, %
Detectable bias with
Egger test?
Decompression 27.1 (15.1–39.1) 12.8 (1.7 to 24.0) 9 (22) 14.3 (−2.1 to 30.7) +++ (p < 0.001)
Exercise 14.4 (6.4–22.3) 1.9 (−6.9 to 10.7) 7 (35) 12.5 (0.7 to 24.3) − (p = 0.72)
Hypothermia 16.3 (10.3–22.3) 16.3 — (11) — − (p = 0.799)
OEG 20.1 (15.2–24.9) 19.2 (14.4 to 24.0) 1 (53) 0.9 (−5.9 to 7.7) +++ (p < 0.001)
Rho/ROCK
inhibitors
21.3 (16.0–26.6) 15.6 (10.1 to 21.2) 9 (30) 5.7 (−2.0 to 13.4) +++ (p < 0.001)
Stem cells 26.2 (23.9–28.5) 26.2 — (278) — − (p = 0.12)
Abbreviations: BBB = Basso, Beattie, and Bresnahan; BMS = Basso Mouse Scale; CI = confidence interval; OEG = olfactory ensheathing glia.
Different interventions were investigated for the inherent calculated number of reporting bias (missing experiments) and absolute overstatement of efficacy
(delta inflation) byDuval and Tweedie nonparametric trimand fill analysis. This provides an estimate of the number of unpublished studies and an estimate of
what the observed efficacy might have been had these studies been available. When no adjustment is made, either there are not enough data to infer the
number ofmissing studies or there is no publication bias. Egger regressionwas added as an additional test to detect whethermissing data reached significant
levels (right column). Analyses were calculated for each singular intervention.
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Figure 3 Empirical evidence of reporting bias (data asymmetry) in experimental rodent SCI studies (BBB/BMS only cohort)
To allow a more homogeneous group characterized by similar effect sizes (ESs), a rodent analysis was completed identifying the Basso, Beattie, and
Bresnahan (BBB)/BassoMouse Scale (BMS) only group as comparable with regard to themain outcome parameter (improved locomotor function, figure 1B,
red square). Funnel plots illustrating the precision (1 divided by the SEM, y-axis) plotted against the standardized ES (x-axis). Each black dot represents 1
experiment. In the absence of publication bias, the points should resemble an inverted funnel. Black dotted line indicates the reported ES before inclusion of
missing studies; red line, after trim and till analysis. (A) Decompression: reported ES 27.1% (95% confidence interval [CI] 15.1–39.1, n = 22 studies), adjusted
ESs 12.8% (95% CI 1.7–24.0, n = 31). (B) Exercise: reported ES 14.4% (95% CI 6.4–22.3, n = 35), adjusted ES 1.9% (95% CI −6.9 to 10.7, n = 42). (C) Hypothermia:
reported ES 16.3% (95%CI 10.3–22.3) without adjustments. (D) Olfactory ensheathing glia (OEG): reported ES 20.1% (95%CI 15.2–24.9, n = 53), adjusted ES 19.2
(95% CI 14.4–24.0, n = 54). (E) Rho/ROCK inhibitors: reported ES 21.3% (95% CI 16.0–26.6, n = 30), adjusted ES 15.6% (95% CI 10.1–21.2, n = 39). (F) Stem cells:
reported ES 26.2% (95% CI 23.9–28.5) without detection of missing studies.
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observable in the SCI studies from Japan (p = 0.002) and the
United States (p = 0.06). In contrast, in studies from China,
the effect size did not correlate with the quality score.
Discussion
We demonstrate the feasibility and utility of a meta-
epidemiologic approach for systematic assessment of
outcome variability and detection of the presence of bias in
the design and reporting of experimental SCI studies
through a meta-analysis of data from 303 publications in-
cluding 9,535 experimental animals. We provide empirical
evidence for bias in experimental SCI research resulting in
inflated effect sizes, and we report the effect of study design
characteristics on heterogeneity of neurobehavioral
recovery.
Rodent females constitute the largest population used in
preclinical SCI models, with rats outnumbering mice (figures
1 and 2). The analysis of outcome measures confirms open-
field BBB and BMS testing as robust measures of locomotor
recovery characterized by comparable effect sizes. The data re-
emphasize the evidence that a combination of multiple
functional outcome measures examining particular compo-
nents of recovered motor function results in the reporting of
less inflated effect sizes.32 Nonhuman primates were associ-
ated with a large effect size and variability. The Tarlov score
was developed in 195425 and is outdated.
Independent group assignment (blinded SCI induction, al-
location concealment) and blinded assessment (masking) of
outcome are crucial to avoid prevalent selection and evalua-
tion bias; more than half of the studies analyzed lacked
blinding. Lack of blinding was associated with a significant
overstatement of efficacy by 7.2% in the overall cohort when
considering all species and interventions. However, relative to
the effect size of tested interventions, up to 55% of inter-
ventional effect may be inflated and attributable to the lack of
blinding (e.g., 7.2% of 13.1% for exercise as an intervention).
In addition to blinding, compliance with regulatory require-
ments is considered a measure of study quality.21 Lack of
reporting of this criterion was associated with an over-
statement of efficacy by 5.6%.
To provide a more homogeneous subcohort for studying
differential effects of intervention type, lesion level, sex, injury
modality, geographic location of publishing laboratory, effect
durability, and missing data (publication/reporting bias), the
subsequent analysis was restricted to a rodent BBB/BMS only
cohort (n = 7,613).
Interventions
We identified 6 different therapeutic interventions, including
the spectrum of cellular therapies (stem cells, OEG), sys-
temically applied approaches (hypothermia, Rho/ROCK
inhibitors), and rehabilitative (exercise) and surgical inter-
ventions (decompression). Four of 6 interventions (67%)
were characterized by data asymmetry, attributable largely to
Table 3 Study characteristics of the BBB/BMS subanalysis based on geography
China (n = 2,177) Japan (n = 960) United States (n = 2,039)
ES 95% CI No. p Value ES 95% CI No. p Value ES 95% CI No. p Value
Quality score
1 22.5 4.4 to 40.6 89 0.53 49.1 33.8 to 64.4 132 0.002 38.7 14.3 to 63.1 112 0.06
2 29.4 18.7 to 40.1 395 32.0 20.1 to 43.9 250 18.3 2.6 to 34. 362
3 37.2 30.8 to 43.7 613 16.1 8.9 to 23.4 183 17.9 6.4 to 29.3 425
4 30.4 21 to 39.8 613 23.0 −0.2 to 46.1 78 11.8 −4 to 27.7 369
5 29.6 19.7 to 39.5 395 18.6 7.3 to 29.9 247 4.0 −12.2 to 20.2 437
6 27.4 2.6 to 52.2 52 18.6 0.7 to 36.5 70 22.3 5.9 to 38.8 334
7 22.9 −16.9 to 62.8 20 — —
Type of SCI
Compression 35.0 22.8 to 47.1 336 0.35 21.5 7.1 to 35.8 117 0.37 10.5 −33.5 to 54.5 45 0.26
Hemisection 33.9 22.8 to 45. 367 19.6 −1.6 to 40.7 109 30.6 13.6 to 47.6 330
Transection 28.2 19.8 to 36.5 813 9.3 −12.3 to 30.9 45 8.5 −10.4 to 27.3 172
Contusion 34.7 28 to 41.3 661 26.0 20.1 to 31.9 689 15.2 9.6 to 20.7 1,492
Abbreviations: BBB = Basso, Beattie, and Bresnahan; BMS = Basso Mouse Scale; CI = confidence interval; ES = effect size; SCI = spinal cord injury.
For amore detailed analysis on varying effect sizes dependent on the location of the publishing laboratory, we focused on countries with a robust number of
experiments. Representative countries include Japan (n = 960 rodents), the United States (n = 2,039), and China (n = 2,177). This analysis corresponds to the
overall findings displayed in figure 2E, suggesting regional effects with regard to the reporting of study results.
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missing data. For 3 of 6 interventions (50%), our analysis
identified an overstatement of efficacy (table 2). The effect
sizes of classic acute care interventions (decompressive sur-
gery and hypothermia) were larger than the effect sizes of
rehabilitation interventions. Effects of exercise interventions
display a large CI and point to the existence of variable factors
determining rehabilitation efficacy. These results also suggest
that rehabilitation cannot fully compensate for what has been
lost during acute care and could emphasize the therapeutic
value of optimal specialized acute SCI care. Retrospective
clinical studies of acute care interventions such as decom-
pressive surgery support this notion.34,35
SCI lesion level
We provide evidence that in addition to varying lesion se-
verity, the distance from the lesion to the lumbosacral motor
pools is an important determinant of responsiveness to
treatment (figure 2B). The more distant the lesion is, the
lower the neurologic recovery is. The increase of effect size
per spinal level, descending along the neuraxis, is not linear.
The effect size per lesion level distal to Th10 results in a re-
markable increased step of effect sizes. This stratification
confirmed the biological plausibility of the SCI model, with
increasing effect size the closer the lesion is located to lum-
bosacral motor pools, suggesting the propagation of intrinsic
repair/regeneration pathways as the underlying mechanism of
recovery. Less severe high cervical models will naturally allow
higher compensatory plasticity, contributing to larger effect
sizes, which render them mechanistically noncomparable to
complete transection or contusion SCI applied to low cervical
to low thoracic sites.
Sex
Female rodents displayed smaller effect sizes compared to
males (figure 2C). Thoracic SCI is the most prevalent cohort
modeling experimental SCI (figure 2B), matching to some
degree with lower functional recovery in women after thoracic
(T2-8) SCI. However, this is only a transient effect and is no
longer detectable 1 year after human SCI.36
Injury type
Contusion injury was the most severe injury, characterized by
smallest effect sizes in response to interventional therapy.
This is consistent with evidence of injury exacerbation
extending both rostrally and caudally from the lesion site after
contusion, whereas even after complete transection, injury
remains localized to the initial lesion site.32,37 Static clip
compression injury is a slightly less severe SCI paradigm
(figure 2D).
Geographic effects
Stratification for the location of publishing laboratory revealed
differences (figure 2E). Study results from Japan and the
United States showed an inverse association between effect
sizes and quality, confirming findings from a previous meta-
analysis in animal research,21 whereas studies from China did
not (table 3). Chinese studies demonstrated smaller
variability of outcomes compared to studies from Japan and
the United States. Larger effect sizes concomitant with smaller
CIs are consistent with the suggestion that animals considered
to be outliers have been removed from further analysis, con-
tributing to attrition bias.38 The data suggest geographic dif-
ferences with regard to the reporting of study results and
emphasize the importance of reporting attrition and its
reasons.
Unstable (transient) treatment effects
We observed an intermittent decline of effect sizes from 8
weeks after SCI on, suggesting the presence of concomitant
processes that undermine gained locomotor functions. Sev-
eral processes may account for this, including delayed neu-
rodegeneration39 and salutatory nerve conduction failure of
intact axons at the chronic lesion site.40,41 Our results suggest
that an observational time frame of ≥8 weeks is required to
report durable effects. The data indicate a risk for transient
interventional effects and the need to favor long-term over
short-term outcome measures, in line with other models of
acute CNS injury.42
Reporting bias (missing data)
We provide empirical evidence of missing data. Trim and fill
analysis of the entire BBB/BMS only cohort identified miss-
ing data. This was confirmed by Egger regression (table 2).
Publication bias is a fundamental problem in preclinical re-
search across many disciplines.30 The presence of such bias
leads to inflated effect sizes and skewed biometric planning of
clinical trials and jeopardizes the successful translation of SCI
therapies from bench to bedside. The fact that for some of the
interventions no publication bias could be detected may have
several reasons and does not automatically imply that it is not
present at all. The analysis of interventions with a small
number of experiments is most likely underpowered. In ad-
dition, even for interventions with large sample sizes, the
precision of experiments may be falsely increased due to un-
explored attrition.
Regarding limitations of this study, we were able to include
only data from studies in the public domain. Second, for both
study quality and study design characteristics, we relied on
published information. When relevant data were not available
(the sex of a cohort of animals or measures taken to reduce
bias), we have either analyzed them as not known or inferred
that measures that were not reported did not occur. Third, we
present a series of univariate meta-regression analyses. Mul-
tivariate meta-regression or stepwise partitioning of hetero-
geneity might provide more robust insights, but these
techniques are not well established today. Fourth, our analysis
depended on the validity of the scales used, which has been
questioned.43 Fifth, translation into human SCI might be
dampened by limitations of the animal SCI model, affecting
the external validity, such as the absence of polytrauma (in-
cluding vertebrae fractures). Finally, we accept the weakness
of the presented meta-analysis, which combines various ani-
mal models of specific SCI treatments within a very large
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dataset and assumes that random-effect meta-regression can
account for this. Detecting the likelihood of preventable bias is
still a comparatively novel but imperfect science because
reporting standards are generally poor. However, while im-
perfect, the analysis represents best evidence available, rep-
resenting one of the largest studies on SCI animal models to
date.
In this study, we provide empirical evidence for differential
outcome characteristics attributable to distinct SCI models
and experimental designs. We observed evidence for transient
treatment effects, as well as evaluation and publication bias,
which diminish the experimental validity and could cause
clinical trials to follow false leads. The presence of publication
bias in preclinical SCI research confirms the endemic pres-
ence of underlying bias in science,11 rather than being specific
to SCI.29 Bias in animal SCI experiments erodes the predictive
value for translation into human SCI trials. Bias is not re-
stricted to experimental testing but also occurs later in the
translational spectrum in early clinical testing.44
The SCI field is proactively responding to this challenge.45
Our data inform 4 recommendations to enhance the pre-
dictive value of experimental SCI research for a higher like-
lihood of translational success:
1. Reduce bias at the benchside46 through allocation
concealment and blinded assessment of outcome; by
reporting animals excluded from the analysis38; and by
providing a sample size calculation, inclusion and
exclusion criteria, randomization, and transparent report-
ing of potential conflicts of interest and study
funding.12,42
2. Report nonconfirmatory (negative or neutral) results,
which are persistently underrepresented in the public
domain.
3. Use international experimental and reporting standards
in preclinical SCI studies according to the Minimum
Information About a Spinal Cord Injury Experiment47 or
Animal Research: Reporting of In Vivo Experiments
guidelines48 to reduce study design variability.
4. Develop data-sharing models49–51 and international
cooperation in preclinical SCI research to learn more
about underlying differences.
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